Capecitabine
Lennox Gastaut Syndrome
Jazz PharmaceuticalsSmall moleculePhase 3Dormant
B
62/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 89/ 100
Competitive context
5 Active assets in the Lennox Gastaut Syndrome cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Benzeneethanamine, N-ethyl-?-methyl-4-(trifluoromethyl)-, hydrochloride, (±)- University of Chicago | Phase 3 | BB |
Bexicaserin Longboard Pharmaceuticals | Phase 2 | BB |
zx008 Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc. | Phase 3 | BB |
Carisbamate SK Life Science, Inc. | Phase 3 | BB |
Clemizole Epygenix | Phase 3 | B |
Fycompa Eisai Inc. | Phase 3 | B |
Bmb-101 Bright Minds Biosciences Pty Ltd | Phase 2 | CCC |
Same molecule, other indications
Capecitabine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →